First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued

First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued

TRAXV - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$796.64M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
First Tracks Biotherapeutics, Inc. Ordinary Shares When-IssuedFirst Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued-12.5----

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$796.64 Million
Enterprise Value$632.96 Million
Earnings per Share$0
Beta0
Outstanding Shares35,390,679

Return

Return on EquityNaN%ROE
Return on AssetsNaN%
Return on Invested CapitalNaN%

Valuation & Multiples

P/E Ratio-12.49P/E Ratio
PEG42.64PEG
Price to Sales-Price to Sales
Price to Book Ratio5.63Price to Book Ratio
Enterprise Value to Revenue-
Enterprise Value to EBIT-
Enterprise Value to Net Income-
Total Debt to Enterprise0.01
Debt to Equity0.03Debt to Equity

Revenue Sources

No data

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued

104 employees
CEO: Daniel R. Faga

First Tracks Biotherapeutics, Inc. is a clinical-stage biotechnology firm focused on advancing antibody therapies. These innovative treatments are designed to modulate immune system pathways that contribute to autoimmune and inflammatory...

First Tracks Biotherapeutics Ordinary Shares When-Issued Insider Information FAQ

Stockcircle tracks 3 top investors with a current 13F position in First Tracks Biotherapeutics Ordinary Shares When-Issued. Holdings come from the latest quarterly 13F filings filed with the SEC.

In the latest 13F quarter on Stockcircle, 3 top investors increased or opened positions among tracked top investors. Changes are based on reported share counts in their quarterly filings, not day-to-day trading.

Stockcircle shows 1 open-market insider sale for First Tracks Biotherapeutics Ordinary Shares When-Issued in the last six months from SEC Form 4 reports by executives, directors, and other insiders.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.